三鑫医疗 reported revenue of ¥0.84B for the period ended 2026-06-30, +10.0% year on year. Net income was ¥0.15B, a 17.3% net margin on a 36.3% gross margin. The largest revenue line is 血液净化类 at 85% of the total. Free cash flow for the period was ¥0.08B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.84B | +10.0% |
| Gross profit | ¥0.30B | — |
| Operating income | ¥0.17B | — |
| Net income | ¥0.15B | +14.0% |
| Gross margin | 36.3% | Net margin 17.3% |
| Revenue Q/Q | +4.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 血液净化类 | ¥0.71B | 85.0% |
| 给药器具类 | ¥0.07B | 8.8% |
| 心胸外科类 | ¥0.03B | 4.1% |
| 其他类 | ¥0.02B | 2.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.53B | 63.7% |
| R&D | ¥0.04B | 4.7% |
| SG&A | ¥0.10B | 11.5% |
| Tax & other | ¥0.02B | 2.7% |
| Item | Amount |
|---|---|
| Total assets | ¥2.47B |
| Total liabilities | ¥0.90B |
| Shareholders' equity | ¥1.57B |
| Equity / assets | 63.6% |
| Operating cash flow | ¥0.14B |
| Capital expenditure | ¥0.06B |
| Free cash flow | ¥0.08B |
| Cash conversion (OCF / net income) | 107% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
深信服 ・ 航天智装 ・ 赛微电子 ・ 赢合科技 ・ 全志科技 ・ 汤姆猫 ・ ST惠伦 ・ 田中精机 ・ ST华铭 ・ 迈克生物 ・ 星徽股份 ・ 高伟达
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies